A new clinical trial run by the Australasian Leukaemia & Lymphoma Group* (ALLG) is currently open to eligible people with chronic myeloid leukaemia (CML).

CML13 – leading doctors, Dr David Yeung and Professor Tim Hughes

The CML13 trial is evaluating the most appropriate treatments for CML patients and the purpose of this important clinical Phase II trial is to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase  CML.

Asciminib (previously known as ABL001) is a novel allosteric inhibitor of BCR-ABL that has demonstrated good tolerance and efficacy in CML patients who are resistant or intolerant to the currently available tyrosine kinase inhibitor (TKI) drugs.

This trial is open to recruitment at the following sites:

Victoria – Peter MacCallum Cancer Centre

New South Wales – Concord Hospital

South Australia – Royal Adelaide Hospital.

More locations to open over coming months.

For more information on this and other current clinical trials in CML, visit the ALLG website, or speak to your treating haematologist.

* The ALLG is the only not-for-profit collaborative clinical trial group in Australia and New Zealand delivering research projects focused on blood cancers. The ALLG’s purpose is to achieve better treatments and better lives for people with AML and other blood cancers. ALLG clinical trials are taking place at 93 accredited hospital sites and cancer centres across the country and more than 800 physicians and haematologists, nurses, scientists, and professional support staff are ALLG members.